Loading...
XNASPVLA
Market cap18mUSD
Jan 10, Last price  
13.97USD
1D
-1.96%
1Q
-15.59%
Jan 2017
-87.57%
IPO
-93.87%
Name

Pieris Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:PVLA chart
P/E
—
P/S
0.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.15%
Rev. gr., 5y
8.03%
Revenues
43m
+65.28%
11,383,3229,879,9105,365,0542,931,9315,830,67425,275,00029,101,00046,279,00029,323,00031,418,00025,902,00042,810,000
Net income
-25m
L-21.47%
-2,320,54666,196-9,849,964-14,058,641-22,799,164-17,647,000-26,754,000-23,755,000-37,230,000-43,366,000-31,253,000-24,543,000
CFO
-54m
L-10.20%
-9,087,479-3,076,482-5,065,701-12,705,480-14,387,93449,754,000-1,066,000-52,467,000-45,896,000-7,660,000-59,932,000-53,819,000
Earnings
Mar 27, 2025

Profile

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
URL
https://www.pieris.com/
IPO date
Dec 18, 2014
Employees
127
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
42,810
65.28%
25,902
-17.56%
Cost of revenue
100,455
72,156
Unusual Expense (Income)
NOPBT
(57,645)
(46,254)
NOPBT Margin
Operating Taxes
(2,024)
Tax Rate
NOPAT
(57,645)
(44,230)
Net income
(24,543)
-21.47%
(31,253)
-27.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
19,795
7,214
BB yield
-120.76%
-9.35%
Debt
Debt current
859
Long-term debt
24,488
Deferred revenue
18,734
Other long-term liabilities
18,734
Net debt
(26,366)
(33,822)
Cash flow
Cash from operating activities
(53,819)
(59,932)
CAPEX
(171)
(1,041)
Cash from investing activities
12,002
(21,236)
Cash from financing activities
19,795
7,214
FCF
(37,340)
(41,896)
Balance
Cash
26,366
59,169
Long term investments
Excess cash
24,226
57,874
Stockholders' equity
(314,838)
(290,601)
Invested Capital
341,596
369,101
ROIC
ROCE
EV
Common stock shares outstanding
1,126
927
Price
14.56
-82.50%
83.20
-72.49%
Market cap
16,392
-78.75%
77,139
-68.38%
EV
(9,974)
43,317
EBITDA
(55,864)
(43,474)
EV/EBITDA
0.18
Interest
10,197
Interest/NOPBT